期刊文献+

T1G3膀胱移行细胞癌复发特点分析 被引量:4

Characteristics of recurrence of T1G3 transitional cell carcinoma of bladder
原文传递
导出
摘要 目的分析T1G3膀胱移行细胞癌的复发特点。方法自北京协和医院1993至2003年的复发性膀胱移行细胞癌病例中,选择首次治疗方法相同的T1期病例72例,按病理分级分组,G3组37例,G1-2组35例。分别对首次复发时间,复发次数,复发肿瘤的数量、形态、病理分期以及复发后治疗方法等资料进行统计分析。结果T1G3组第1、2、3年及4年以上的复发率分别为29·7%、40·5%、18·9%及10·8%,T1G1-2组分别为14·3%、34·3%、31·4%及20·0%,两组比较差异有统计学意义(P=0·025)。T1G3组单次复发的4例(10·8%),3次以上复发的20例(54·0%),T1G1-2组分别为17例(48·6%)和6例(17·2%),两组比较差异有统计学意义(P<0·01)。T1G3组复发后肿瘤病理分期T2期以上的32例(86·5%),T1G1-2组15例(42·8%)。T1G3组最后一次复发后进行膀胱部分切除或膀胱全切治疗的35例(94·6%),T1G1-2组20例(57·1%),两组比较差异有统计学意义(P<0·01)。结论T1G3膀胱移行细胞癌治疗后近期易复发,且复发次数多,复发后多数发展为浸润癌,应当引起临床治疗上的重视,注意术后随访。 Objective To investigate the characteristics of recurrence of T1G3 transitional cell carcinoma (TCC) of bladder. Methods The clinical data of 72 patients with TCC of bladder of the stage T1, 37 being of the stage T1 G3 and 35 being of the stage T1 G1-2, who underwent the initial treatment by transurethral resection of bladder tumor plus post-operative bladder infusion were analyzed. Results The first, second, third, and fourth year recurrent rates of the T1 G3 group were 29.7% , 40.5% , 18.9% , and 10.8% respectively, all significantly higher than those of the T1G2 group (14.3% , 34.3% , 31.4%, and 20.0% respectively, t = 1. 994, P =0.025 ). The rate of recurrence for only time was 10.8% in the TI G3 group (4/37), significantly lower than that of the T1G1-2 group ( 17/35, 48.6% , P 〈0.01 ). The rate of recurrence for more than 3 times was 54.0% in the T1 G3 group ( 20/37 ), significantly higher than that of the T1G1-2 group (6/35, 17.2% , P〈0.01 ). The rate of recurrent tumor at the pathological stage over T2 was 86.5% (32/37) in the T1G3 group, higher than that of the T1G1-2 group (42.8% , 15/35). The rate of partial or total cystectomy at the last recurrence in the T1G3 group was 94.6% (35/37), significantly higher than that of the TI G1-2 group (57.1%, 20/35, X2 = 14.00, P〈0.05 ). Conclusion A kind of dangerous bladder cancer, TCC at the stage T1G3 is apt recur soon after the treatment with a high recurrent frequency. Most recurrent tumors evolve into invasive cancer.
出处 《中华医学杂志》 CAS CSCD 北大核心 2006年第19期1305-1308,共4页 National Medical Journal of China
关键词 膀胱肿瘤 移行细胞 复发 Bladder neoplasms Carcinoma Transitional cell Recurrence
  • 相关文献

参考文献15

  • 1Dell'Orto P,Trinchieri A,D'Addezio F,et al.pT1G3 bladder carcinoma:our experience.Arch Ital Urol Androl,1996,68:9-11.
  • 2Freeman JA,Esrig D,Stein JP,et al.Radical cystectomy for highrisk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction.Cancer,1995,76:833-839.
  • 3Stein JP.Indications for early cystectomy.Semin Urol Oncol,2000,18:289-295.
  • 4Herr HW.Tumor progression and survival in patients with T1G3 bladder tumors:15-year outcome.Br J Urol,1997,80:762-765.
  • 5Sriprasad SI,Hopster D,Muir GH,et al.The biological characteristics of pT1G3 bladder tumors are the same as muscle invasive cancer:a study of cell proliferation and molecular markers of aggressiveness.J Urol,2001,165:192.
  • 6肖泽均,郑闪,陈汶,张海峰,李长岭,高燕宁.Survivin蛋白在膀胱移行细胞癌组织中的表达及临床意义[J].中华医学杂志,2004,84(23):1977-1979. 被引量:7
  • 7Duggan B,Williamson K.Molecular markers for predicting recurrence,progression and outcomes of bladder cancer (do the poster boys need new posters?).Curr Opin Urol,2004,14:277-286.
  • 8Queipo Z,Ruiz C,Palmero M,et al.Prognostic value for progression of the regulating proteins of the cellular cycle in PT1 G3 bladder tumors.Actas Urol Esp,2005,29:261-268.
  • 9Shariat SF,Kim JH,Raptidis G,et al.Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.Urolo 2003,61:1140-1145.
  • 10朱育焱,孔垂泽,曾宇,庞国友,杨春明,孙志熙.细胞黏附、多药耐药及细胞增殖在T_1G_3型浅表膀胱癌近期复发中的作用[J].中华外科杂志,2003,41(12):893-896. 被引量:9

二级参考文献18

  • 1LaCasse EC,Baird S,Korneluk RG, et al. The inhibitors of apoptosis(IAPs) and their emerging role in cancer . Oncogene, 1998, 17:3247.
  • 2Ikeguchi M,Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer, 2002, 87: 883-887.
  • 3Kim HS,Shiraki K,Park SH, et al. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res, 2002, 22(2A):805-808.
  • 4Nasu S, Yagihashi A,Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002,22:1839-1843.
  • 5Yu J,Leung WK,Ebert MP, et al. Increased expression of survivin in gastric cancer patients and in first degree relatives.Br J Cancer,2002,87: 91-97.
  • 6Ambrosini G,Adida C,Altier DC. A novel antiapoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med, 1997, 3: 917.
  • 7Cohen C,Lohman CM,Cotsonis G,et al. Survivin expression in ovarian carcinoma:correlation with apoptotic markers and prognosis. Mod Pathol, 2003,16:574-583.
  • 8Suzuki A,Ito T,Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene, 2002, 19: 1346-1353.
  • 9Harfouche R,Hassessian HM,Guo Y, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cell. Microvasc Res, 2002, 64: 135-147.
  • 10Swana HS,Grossman D,Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med,1999,341:452-453.

共引文献14

同被引文献33

  • 1Louis R,Andrew C,Atan W,et al.Campbell-Walsh Urology.9th ed.USA:Elsevier Inc,2007:2447-2467.
  • 2Burger M,van der Aa MN,van Oers JM,et al.Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status:a prospective study.Eur Urol,2008,54:835-844.
  • 3Sorbin DH,Witteking CH.TNM classification of Malignant Tumors.6th ed.New York:Wiley-Liss,2002:199-202.
  • 4Oosterlinck W,Witjes F,Sylvester R,et al.Diagnostic and prognostic factors in non-mnscle-invasive bladder cancer and their influence on treatment and outcomes.Eur Urol,2008,7 Suppl 7:516-523.
  • 5Louis LS.Urethelial cancer biomarkers for detection and surveillance.Urology,2006,67(3Suppl 1):25-34.
  • 6Mitra AP,Datar RH,Cote RJ.Molecular pathways in invasive bladder cancer:new insights into mechanisms,progression,and target identification.J Clin Oncol,2006,24:5552-5564.
  • 7Queipo Z,Ruiz C,Palmere M,et al.Prognostic value for progression of the regulating p roteins of the cellular cycle in PT1G3 bladder tumors.Actas Urol Esp,2005,29:261-268.
  • 8Solsona E,Iborra I,Dumont R,et al.The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.J Urol,2000,164:685-689.
  • 9Brnsach MR,Bohle A,O'Dannell MA.Intravesical instillation treatment of non-muscle-invasive bladder cancer.Eur Urol,2009,7 Suppl 8:549-555.
  • 10Kirkali Z,Chan T,Manoharan M,et al.Bladder cancer:epidemiology,staging and grading,and dingnosis.Urology,2005,66:4-34.

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部